Details

Autor(en) / Beteiligte

• Vanek, Vincent W.
• Borum, Peggy
• Buchman, Alan
• Fessler, Theresa A.
• Howard, Lyn
• Jeejeebhoy, Khursheed
• Kochevar, Marty
• Shenkin, Alan
• Valentine, Christina J.

Titel

A.S.P.E.N. Position Paper: Recommendations for Changes in Commercially Available Parenteral Multivitamin and Multi–Trace Element Products

Ist Teil von

• Nutrition in clinical practice, 2012-08, Vol.27 (4), p.440-491

Ort / Verlag

Los Angeles, CA: SAGE Publications

Erscheinungsjahr

2012

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• The parenteral multivitamin preparations that are commercially available in the United States (U.S.) meet the requirements for most patients who receive parenteral nutrition (PN). However, a separate parenteral vitamin D preparation (cholecalciferol or ergocalciferol) should be made available for treatment of patients with vitamin D deficiency unresponsive to oral vitamin D supplementation. Carnitine is commercially available and should be routinely added to neonatal PN formulations. Choline should also be routinely added to adult and pediatric PN formulations; however, a commercially available parenteral product needs to be developed. The parenteral multi–trace element (TE) preparations that are commercially available in the U.S. require significant modifications. Single-entity trace element products can be used to meet individual patient needs when the multiple-element products are inappropriate (see Summary/A.S.P.E.N. Recommendations section for details of these proposed modifications).